Australian Clinical Labs Completes $22 Million Share Buy-Back, Below Its 19.5 Million-Share Cap
ACL: $3.32 +2.15% · MC: $619M
Australian Clinical Labs’ final notification records that it bought back about 9.3 million shares for approximately $22 million, below the authorised maximum of 19.5 million shares. The on-market buy-back ran from November 2025 to November 2026 and was subject to the company’s capital position and other factors.

Comments